GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Gross-Profit-to-Asset %

INVO Bioscience (INVO Bioscience) Gross-Profit-to-Asset % : 14.81% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. INVO Bioscience's annualized Gross Profit for the quarter that ended in Mar. 2024 was $2.90 Mil. INVO Bioscience's average Total Assets over the quarter that ended in Mar. 2024 was $19.60 Mil. Therefore, INVO Bioscience's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 14.81%.


INVO Bioscience Gross-Profit-to-Asset % Historical Data

The historical data trend for INVO Bioscience's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Bioscience Gross-Profit-to-Asset % Chart

INVO Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.28 14.90 37.50 -0.40 8.69

INVO Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.13 3.75 12.07 9.81 14.81

Competitive Comparison of INVO Bioscience's Gross-Profit-to-Asset %

For the Medical Devices subindustry, INVO Bioscience's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Bioscience's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, INVO Bioscience's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where INVO Bioscience's Gross-Profit-to-Asset % falls into.



INVO Bioscience Gross-Profit-to-Asset % Calculation

INVO Bioscience's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=1.086/( (4.104+20.888)/ 2 )
=1.086/12.496
=8.69 %

INVO Bioscience's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=2.904/( (20.888+18.318)/ 2 )
=2.904/19.603
=14.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


INVO Bioscience Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Bioscience (INVO Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880